APA (7th ed.) Citation

Stewart, A. G., Paterson, D. L., Young, B., Lye, D. C., Davis, J. S., Schneider, K., . . . (ASID-CRN), M. T. I. a. t. A. S. f. I. D. C. R. N. (2021). Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infectious Diseases, 8(8), 1. https://doi.org/10.1093/ofid/ofab387

Chicago Style (17th ed.) Citation

Stewart, Adam G., et al. "Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing Enterobacter Spp, Citrobacter Freundii, Morganella Morganii, Providencia Spp, or Serratia Marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)." Open Forum Infectious Diseases 8, no. 8 (2021): 1. https://doi.org/10.1093/ofid/ofab387.

MLA (9th ed.) Citation

Stewart, Adam G., et al. "Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing Enterobacter Spp, Citrobacter Freundii, Morganella Morganii, Providencia Spp, or Serratia Marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)." Open Forum Infectious Diseases, vol. 8, no. 8, 2021, p. 1, https://doi.org/10.1093/ofid/ofab387.